Prognostic Value of BNP Reduction During Hospitalization in Patients With Acute Heart Failure.


Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 10 12 2018
revised: 23 03 2019
accepted: 04 04 2019
pubmed: 10 4 2019
medline: 15 8 2020
entrez: 10 4 2019
Statut: ppublish

Résumé

Prognostication of patients discharged after acute heart failure (AHF) hospitalization remains challenging. Body weight (BW) reduction is often used as a surrogate marker of decongestion despite the paucity of evidence. We thought to test the hypothesis that B-type natriuretic peptide (BNP) reduction during hospitalization has independent prognostic value in AHF. We studied the prognostic predictability of percentage BNP reduction achieved during hospitalization in patients from the REALITY-AHF study. Percentage BNP reduction was defined as (BNP on admission - BNP at discharge) / BNP on admission × 100. The primary endpoint was 1-year all-cause death. In 1028 patients (age, 77 ± 13 years; 57% male; left ventricular ejection fraction, 47 ± 16%) with AHF, median BNP level at admission was 747 ng/L (interquartile range, 439-1367 ng/L) and median percentage BNP reduction was 62.5% (interquartile range, 36.5-78.5%). The smallest percentage BNP reduction quartile had more than 2-fold higher risk of all-cause death than the greatest quartile (23.0% vs 9.7%, P< .001). After adjusting for covariates including BNP at discharge, the percentage BNP reduction was significantly associated with all-cause death (hazard ratio 0.96, 95% confidence interval 0.93-0.99, P= .032), whereas percentage BW reduction was not. Percentage BNP reduction was more predictive in patients with heart failure with reduced ejection fraction than in those with preserved ejection fraction. The prognostic value of percentage BNP reduction during hospitalization was superior to that of percentage BW reduction and was independent of other risk markers, including BNP at discharge.

Sections du résumé

BACKGROUND BACKGROUND
Prognostication of patients discharged after acute heart failure (AHF) hospitalization remains challenging. Body weight (BW) reduction is often used as a surrogate marker of decongestion despite the paucity of evidence. We thought to test the hypothesis that B-type natriuretic peptide (BNP) reduction during hospitalization has independent prognostic value in AHF.
METHODS AND RESULTS RESULTS
We studied the prognostic predictability of percentage BNP reduction achieved during hospitalization in patients from the REALITY-AHF study. Percentage BNP reduction was defined as (BNP on admission - BNP at discharge) / BNP on admission × 100. The primary endpoint was 1-year all-cause death. In 1028 patients (age, 77 ± 13 years; 57% male; left ventricular ejection fraction, 47 ± 16%) with AHF, median BNP level at admission was 747 ng/L (interquartile range, 439-1367 ng/L) and median percentage BNP reduction was 62.5% (interquartile range, 36.5-78.5%). The smallest percentage BNP reduction quartile had more than 2-fold higher risk of all-cause death than the greatest quartile (23.0% vs 9.7%, P< .001). After adjusting for covariates including BNP at discharge, the percentage BNP reduction was significantly associated with all-cause death (hazard ratio 0.96, 95% confidence interval 0.93-0.99, P= .032), whereas percentage BW reduction was not. Percentage BNP reduction was more predictive in patients with heart failure with reduced ejection fraction than in those with preserved ejection fraction.
CONCLUSIONS CONCLUSIONS
The prognostic value of percentage BNP reduction during hospitalization was superior to that of percentage BW reduction and was independent of other risk markers, including BNP at discharge.

Identifiants

pubmed: 30965102
pii: S1071-9164(18)31340-X
doi: 10.1016/j.cardfail.2019.04.004
pii:
doi:

Substances chimiques

Biomarkers 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

712-721

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Nobuyuki Kagiyama (N)

Department of Cardiology, The Sakakibara Heart Institute of Okayama, Okayama, Japan; Division of Cardiology, West Virginia University, Morgantown, West Virginia; Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Takeshi Kitai (T)

Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.

Akihiro Hayashida (A)

Department of Cardiology, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Tetsuo Yamaguchi (T)

Department of Cardiology, Japanese Red Cross Musashino Hospital, Tokyo, Japan.

Takahiro Okumura (T)

Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Keisuke Kida (K)

Department of Pharmacology, St. Marianna University School of Medicine, Kawasaki, Japan.

Atsushi Mizuno (A)

Department of Cardiology, St. Luke's International Hospital, Tokyo, Japan.

Shogo Oishi (S)

Department of Cardiology, Himeji Cardiovascular Center, Himeji, Japan.

Yasutaka Inuzuka (Y)

Department of Cardiology, Shiga Medical Center for Adults, Moriyama, Japan.

Eiichi Akiyama (E)

Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.

Satoshi Suzuki (S)

Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.

Masayoshi Yamamoto (M)

Cardiovascular Division, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Akane Shimizu (A)

Departments of Pharmacy, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Yu Urakami (Y)

Departments of Pharmacy, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Misako Toki (M)

Clinical Laboratory, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Shingo Aritaka (S)

Clinical Laboratory, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Kozue Matsumoto (K)

Departments of Nursing, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Noriko Nagano (N)

Departments of Nursing, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Keizo Yamamoto (K)

Department of Cardiology, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Yuya Matsue (Y)

Department of Cardiovascular Medicine, Juntendo University, Tokyo, Japan; Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Juntendo University School of Medicine, Tokyo, Japan. Electronic address: yuya8950@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH